Mucormycosis research for cancer patients with infections
Part of Infections clinical trials.
This study gathers samples and data from cancer patients who have certain infections (like mucormycosis or aspergillosis) or are at risk for fungal infections. The goal is to better understand how to diagnose and treat these infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 100 years old.
- You have cancer and at least one of these: a fungal infection called mucormycosis or aspergillosis, a bacterial lung infection, or you are at risk for a fungal infection without having one yet.
- You are willing to have routine medical procedures like blood draws, a lung scope (bronchoscopy), or tissue samples as part of your normal care.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for specific lab “biomarkers” in people with mucormycosis, a serious fungal infection. It compares results with people who have higher infection risk but no active infection, to help doctors diagnose and track this illness more accurately.
This study monitors how the antifungal drug isavuconazole works in children's bodies. It aims to find the right dose for treating serious fungal infections.
This trial tests a combination of two antifungal medications (liposomal amphotericin B and posaconazole or isavuconazole) to treat a serious fungal infection called mucormycosis in people with blood cancers like leukemia or lymphoma. The goal is to see if this combination is safe and works well.
This study looks at how immune system problems relate to fungal infections, using medical records and lab tests on blood and tissue. It may help researchers understand the cause of these infections—especially for people with inherited immune conditions—and improve future care.
This trial tests antifungal drugs in people with a rare but serious fungal infection in the lungs called mucormycosis. It aims to find which treatment works best and is safest for patients.
This study tracks how your immune system responds to serious mold infections, like aspergillosis or mucormycosis. It may help doctors understand why some infections are hard to treat and could lead to better care.
Hear when a new Mucormycosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.